Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4781137 | 0.77 | NOTUM (0.49) | NOTUMTHRBMTNR1A | |
| SCHEMBL1082973 | 0.77 | NOTUM (0.41) | NOTUMGRM5CYP11B1CYP11B2 | |
| SCHEMBL8593458 | 0.76 | L3MBTL1 (0.46) | NOTUM | |
| SCHEMBL27259961 | 0.75 | NOTUM (0.60) | NOTUM | |
| SCHEMBL27358451 | 0.75 | NPC1 (0.45) | NOTUMGRM5CYP11B1CYP11B2 | |
| SCHEMBL23384700 | 0.75 | NOTUM (0.39) | NOTUMGRM5CYP11B1CYP11B2 | |
| SCHEMBL22717412 | 0.75 | NOTUM (0.39) | NOTUMGRM5CYP11B1CYP11B2 | |
| SCHEMBL3595427 | 0.75 | HTR6 (0.51) | NOTUMGRM5CYP11B1CYP11B2 | |
| SCHEMBL18387670 | 0.74 | UCHL1 (0.46) | NOTUMGRM5CYP11B1CYP11B2 | |
| SCHEMBL22313615 | 0.73 | NOTUM (0.38) | NOTUMGRM5CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | HCRTR1 954/4885HCRTR2 397/4885NOTUM 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.